NUTRAVITA - ALPHA LIPOIC ACID 650MG
Food supplement declared in France, decision dated 6 August 2026
NUTRAVITA - ALPHA LIPOIC ACID 650MG, from Karo Healthcare AB, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: acide lipoïque 650 mg per day. None of the rules we check flags an issue with its declared composition.
- Brand
- NUTRAVITA
- Food business operator placing the product on the market
- Karo Healthcare AB
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 gélule par jour
- Directions for use
- Prendre 1 gélule par jour avec un grand verre d'eau
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women
Declaration 372607, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Substances
| Name | Per day |
|---|---|
| acide lipoïque | 650 mg |
Additives
E464
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Ne pas dépasser la dose journalière recommandée. Si vous prenez des médicaments ou si vous avez des réactions inattendues, consultez votre médecin. Déconseillé chez les personnes diabétiques, ainsi que les femmes enceintes et allaitantes. Tenir hors de la portée des jeunes enfants. Ne convient pas aux personnes de moins de 18 ans. Les compléments alimentaires ne doivent pas être utilisés comme substituts d'un régime alimentaire varié et équilibré et d'un mode de vie sain.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- acide lipoïque
Read the warning, when it applies and the studies cited
DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).
Sources cited by Health Canada (3)
- Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
- Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
- Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article
Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).
Sources cited by Health Canada (4)
- Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
- Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
- Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
- Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : NUTRAVITA
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “NUTRAVITA - ALPHA LIPOIC ACID 650MG: composition and regulation”, https://compoatlas.com/en/supplements/products/372607-nutravita-alpha-lipoic-acid-650mg, updated 15 November 2026.